CARLSBAD, Calif., May 19, 2022 (GLOBE NEWSWIRE) — CB Therapeutics (the “Company”), a biotechnology and precision fermentation company focused on using cellular agriculture to produce environmentally-friendly products for human health, has been granted a new patent covering the use of microorganisms to produce tryptamines and their analogs, such as psilocybin and various other molecules found in…


Previous articleDelix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank
Next articleMindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin